Since the FDA approved recombinant bone morphogenetic protein-2 (rhBMP-2; INFUSE™) as a bone graft substitute (BGS) for spinal fusion, serious safety concerns have arisen, resulting in an unmet need for a universally safe and efficacious BGS. The pro-osteogenic chemokine, CXCL12, improves the efficiency of BMP-2 in promoting bone formation in vivo. Although DBM alone is less efficacious than rhBMP-2, it does contain active growth factor and intrinsic osteoinductivity. Here, we will assess CXCL12 as a DBM adjunct under the hypothesis that CXCL12 incorporation will improve the efficacy of DBM as a BGS for spinal fusion in a rat arthrodesis model.
|Effective start/end date||7/1/15 → 6/30/16|
- Orthopaedic Research and Education Foundation (AGMT- 3/10/15)